Methylprednisolone Sequential Treatment Of Severe Acute Asthma Attack Clinical Study

Objective : Sequential Evaluation methylprednisolone treatment of severe acute asthma attack efficacy and safety.Methods : Severe acute asthma attack 52 patients were divided into groups A and B, have to methylprednisolone 80 mg intravenous drip bid×3d, A sequential oral methylprednisolone tablets 16mg.qd×5 days Group B sequential oral methylprednisolone tablets 8mg×2d also inhaled Salmeterol / Fluticasone (Seretide) 50 ug / 250ug, bid×5 days.Results : Intravenous infusion of three days, two groups symptom score, pulmonary function improved significantly, Sequential treatment were further improved. To 8 days, Group A PEFR value from the pre-treatment of 170±81L.min^-1. increased to 343±102L.min^-1 (P <0.01). Lung function (FEV1) from the pre-treatment of 0.43±0.80 L, rose to 1.17±0.52L (P <0.01). In Group B PEFR values from the pre-treatment of 185±91L.min^-1 increased to 332±112L.min^-1, FEV1 from the treatment of 0.79±0.39 L rose to 1.20±0.50 L (P <0.01) between the two groups no significant difference (P> 0.05). Sputum eosinophil count before treatment by 0.45±1.3, 0.51±1.9 after treatment decreased to 0.07±2.8, 0.04±0.1 between the two groups no significant difference (P> 0.05). Adverse reaction rates were 7.1% and 4.2%, the two groups showed no significant difference (P> 0.05), Merger drug use : A B group in the treatment of paragraphs 4 to 8 days respectively, and one in four cases Application ipratropium bromide (2.5ml. HF bid aerosol inhalation), the rates were 3.57% and 16.67%; 3 cases and 5 cases increased Methylprednisolone tablets (8mg/d) oral, rates were 10.7% and 20.8%, with no significant difference (P> 0.05).Conclusions :Severe acute asthma attack methylprednisolone sequential therapeutic use of oral or inhalation therapy is safe and effective.